Rapid Onset of Action and Quality-of-Life Improvements in Chinese Patients with Plaque Psoriasis Treated with Calcipotriol plus Betamethasone Dipropionate Aerosol Foam in a Randomized Phase 3 Trial - Summary - MDSpire

Rapid Onset of Action and Quality-of-Life Improvements in Chinese Patients with Plaque Psoriasis Treated with Calcipotriol plus Betamethasone Dipropionate Aerosol Foam in a Randomized Phase 3 Trial

  • By

  • Lin Cai

  • Furen Zhang

  • Guoqiang Zhang

  • Yangfeng Ding

  • Yan Zhou

  • Shanshan Li

  • Juan Tao

  • Wei Yan

  • Rong Xiao

  • Bin Yang

  • Jianjun Qiao

  • Xiaoyong Man

  • Zaixing Wang

  • Adam El Mongy Jørgensen

  • Merle Kurvits

  • Jens Strodl Andersen

  • Jianzhong Zhang

  • May 3, 2026

  • 0 min

Share

Objective:

To evaluate the efficacy and safety of Calcipotriol and Betamethasone Dipropionate aerosol foam compared to ointment in Chinese patients with plaque psoriasis.

Key Findings:
  • Cal/BD foam demonstrated superior efficacy compared to Cal/BD ointment in reducing psoriasis severity.
  • Patients experienced rapid improvements in symptoms and quality of life.
  • The safety profile of Cal/BD foam was comparable to that of Cal/BD ointment.
Interpretation:

The findings suggest that Cal/BD foam is an effective and safe treatment option for plaque psoriasis in Chinese patients, potentially enhancing treatment adherence due to rapid symptom relief.

Limitations:
  • The study was limited to a 4-week treatment duration.
  • Results may not be generalizable to populations outside of China.
Conclusion:

Cal/BD aerosol foam is a promising topical therapy for plaque psoriasis, offering rapid therapeutic effects and improved quality of life for patients.

Original Source(s)

Rapid Onset of Action and Quality-of-Life Improvements in Chinese Patients with Plaque Psoriasis Treated with Calcipotriol plus Betamethasone Dipropionate Aerosol Foam in a Randomized Phase 3 Trial

  • by Lin Cai, Furen Zhang, Guoqiang Zhang, Yangfeng Ding, Yan Zhou, Shanshan Li, Juan Tao, Wei Yan, Rong Xiao, Bin Yang, Jianjun Qiao, Xiaoyong Man, Zaixing Wang, Adam El Mongy Jørgensen, Merle Kurvits, Jens Strodl Andersen, Jianzhong Zhang

  • May 3, 2026

Related Content

Coordinated Care Strategies for Psoriasis: An Organized Method for Timely Identification and Referral of Comorbid Conditions

Envudeucitinib: A Next-Generation Allosteric TYK2 Inhibitor - A Comprehensive Review

Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52 Weeks